Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 301–400 of 761
Insulin Metrics: Need for Development of Consensus Standards for Reporting of Insulin Dosing Data
Wolpert, H. A., Polonsky, W. H., & Rodbard, D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0631 · Cited by 10
“22 One recent study showed that elevated levels of diabetes-related emotional distress are associated with more missed boluses over a 9-month period.”
Self-citationPatient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment
Ahmad, A., Khan, M. U., & Aslani, P. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00962-5 · Cited by 9
Food insecurity and medication restricting behavior among persons with diabetes in the United States
McClintock, H. F. D. V., & Imel, B. E. (2022) · Nutrition and Health · doi:10.1177/02601060221115588 · Cited by 8
“Medication restriction among persons with diabetes is associated with inadequate glycemic control, increased utilization of services, higher medical expenditures and mortality rates (Polonsky and Henry, 2016).”
BackgroundNascimento, T., Andrade, A., Pinto, E. A. M., Cabrita, C., Pais, S., & la Puerta, R. D. (2025) · Diabetology · doi:10.3390/diabetology6050033 · Cited by 23
“These complications contribute to increased hospitalization and mortality rates, leading to a substantial rise in direct healthcare costs, not only for national health systems but also for individual patients [17].”
Oliveira, H. C., Neto, D. H., Carvalho, S. D. L., de Barros, R. D. C. L., Neves, M. L. D. S., Andrechuk, C. R. S., Alexandre, N. M. C., & Rodrigues, R. C. M. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01755-w · Cited by 8
“Assessing and promoting medication adherence is paramount, considering the impact of medication regimens in improving glycemic control and decreasing the risk of cardiovascular events and mortality [5, 6].”
BackgroundOdhiambo, C. O., Ablonczy, L., Wright, P. J., Corbett, C. F., Reichardt, S., & Valafar, H. (2023) · JMIR Human Factors · doi:10.2196/42714 · Cited by 12
“Improved medication adherence has the potential to significantly reduce morbidity [60-62], mortality [3,62], and health care costs [60,63-65].”
Nørlev, J. T. D., Hejlesen, O. K., Jensen, M. H., & Hangaard, S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102908 · Cited by 9
The Diabetes Remission in India (DiRemI) study: Protocol for a prospective matched-control trial
TRIPATHI, P., KADAM, N. S., Tiwari, D., Kathrikolly, T., VYAWAHARE, A. R., Sharma, B., GANLA, M. H., & Saboo, B. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306394 · Cited by 8
“However, these pharmacological interventions do not necessarily address the long-term complications associated with type 2 diabetes (T2D), particularly in cases of non-compliance with treatment or ineffective treatment regimens [29].”
BackgroundBonnet, F., Chen, H., Cooper, A., Gomes, M. B., Ji, L., Leigh, P., Ramirez, L., Shestakova, M. V., Shimomura, I., Siddiqui, A., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14476 · Cited by 8
“However, this observation may be explained, at least in part, by improper self-administration of insulin by some patients, and poor long-term adherence because of fear of pain or hypoglycaemia.(18,19) Another potential explanation for this observation is common underdosing of insulin due to fear of causing hypoglycaem…”
BackgroundWeisman, A., TOMLINSON, G. A., Lipscombe, L. L., Perkins, B. A., & HAWKER, G. A. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.09.003 · Cited by 8
Brown, O., & Newton-John, T. R. O. (2022) · Psychology and Health · doi:10.1080/08870446.2022.2032058 · Cited by 11
Wright, E. E., Malone, D. C., Trujillo, J. M., Gill, J., Huse, S., Li, X., Zhou, F. L., Preblick, R., & Reid, T. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.21436 · Cited by 9
Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus
Zargar, A. H., Kalra, S., M., P. K. K., Murthy, S., Negalur, V. B., Rajput, R., Rastogi, A., Saboo, B., Sharma, S. K., Sahay, R. K., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102528 · Cited by 13
Examining the Impact of Polygenic Risk Information in Primary Care
Pacyna, J. E., Ennis, J. S., Kullo, I. J., & Sharp, R. R. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231151766 · Cited by 9
Rai, A., Riddle, M. S., Mishra, R., Nguyen, N., Valine, K., & Fenney, M. (2023) · JMIR Diabetes · doi:10.2196/44297 · Cited by 10
“Medication nonadherence results in undesirable clinical outcomes, especially in patients with chronic diseases, as well as increases in health care resource consumption [1].”
Predicting medication adherence in older Hispanic patients with type 2 diabetes
Caballero, J., Ownby, R. L., Jacobs, R. J., Pandya, N., Hardigan, P. C., & Ricabal, L. C. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170067 · Cited by 8
Valencia, W. M., Florez, H. J., & Palacio, A. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00706-4 · Cited by 10
d’Aquino, A. I., Maikawa, C. L., Nguyen, L. T., Lu, K., Hall, I. A., Jons, C. K., Kasse, C. M., Yan, J., Prossnitz, A. N., Chang, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.28.526057 · Cited by 8
“PNP hydrogels for the prolonged delivery of GLP-1 RAs A) From literature reports it is clear that once weekly dosing frequency does not significantly improve patient compliance compared to a once daily dosing frequency (1).”
BackgroundKlotsman, M., Adin, C. A., Anderson, W. H., & Gilor, C. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.661546 · Cited by 8
“Although limited, data in cats demonstrate that GLP-1RAs generally have similar effects to those seen in human patients and might be useful in treating feline DM (9–16).”
BackgroundInfluentialChen, S.-H., Lee, M., & Pu, C. (2024) · BMC Medicine · doi:10.1186/s12916-024-03324-z · Cited by 9
“Certain modifiable factors, such as a patient’s treat-ment beliefs, physician–patient communication, and dosage form (e.g., hypoglycemic agents vs. insulin), can be used to improve medication adherence [30, 31].”
BackgroundShumye, A. F., Tegegne, M. M., Eticha, B. L., Bekele, M. M., Woredekal, A. T., & Asmare, L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303267 · Cited by 12
“The possible reason might be type of DM, and treatment of DM. Asymptomatic nature of type II DM, older age, and comorbid conditions could be mentioned as the possible reasons that hinder compliance of type II DM patients to their medication [49, 50].”
BackgroundEconomic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France
Heinzlef, O., Molinier, G., van Hille, B., Radoszycki, L., Dourgnon, P., & Longin, J. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-020-00199-7 · Cited by 13
Utilizing Telemedicine for Group Visit Provider Encounters: A Feasibility and Acceptability Study
Patel, T. A., Johnston, C. A., Cardenas, V. J., & Vaughan, E. M. (2021) · INTERNATIONAL JOURNAL OF DIABETES & METABOLIC SYNDROME · doi:10.52106/2771-1331.1001 · Cited by 7
Betancur, L. I., Muñoz, D. L., Guillén, A., Echeverri, F., Balcázar, N., & Acín, S. (2021) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202120201351 · Cited by 8
Lopes, A. C., Roque, F., Morgado, S., Dinis, C., Herdeiro, M. T., & Morgado, M. (2021) · Behavioral Sciences · doi:10.3390/bs11110153 · Cited by 14
Valentine, W. J., Norrbacka, K., & Boye, K. S. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s322390 · Cited by 8
“6 Search strategies utilized high level Medical Subject Heading (MeSH) terms supplemented with free-text terms and search syntax was adjusted as required for use across the different databases (full details of the search strategies used are provided in the Supplementary Tables 1–5).”
Sims, T. J., Boye, K. S., Robinson, S. J., & Kennedy‐Martin, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s367046 · Cited by 12
“Substantial evidence suggests that not using medication as advised is associated with suboptimal glycemic control, increased use of healthcare resources, and higher costs.(6,7) Finally, it is crucial that a person with diabetes (PwD) stays on”
BackgroundWound pH and Surface Temperature as a Predictive Biomarker of Healing in Diabetic Foot Ulcers
Mahindrakar, B., Goswami, A. G., Huda, F., Naithani, M., & Basu, S. (2023) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346231156962 · Cited by 12
“19 Therefore, it is advised that patients must continually be educated and counselled regarding lifelong but ef fi cient treatment strategies to help them reliably continue their medication.”
Henry, R. R., Rosenstock, J., McCarthy, J. F., Carls, G. S., Alessi, T., Yee, J., & Baron, M. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13133 · Cited by 7
“Individuals living with type 2 diabetes (T2D) often develop serious co-morbidities such as heart disease, stroke, kidney failure and blind- ness, which lead to a diminished health-related quality of life (HRQOL).1–3 At present, multiple treatment options for T2D exist that are considered safe and effective in achievin…”
BackgroundInfluentialSelf-citationBerry, E., Davies, M., & Dempster, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.020 · Cited by 10
Reed, P. (2018) · Applied Cognitive Psychology · doi:10.1002/acp.3474 · Cited by 8
Experience gained from the implementation of the fracture liaison service in Greece
Makras, P., Babis, G. C., Chronopoulos, E., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-019-0675-1 · Cited by 7
Efficacy and Safety of Naproxen for Acute Pain
Weisman, S. R. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0064 · Cited by 10
Ergişi, Y., Özdemir, E., Altun, O., et al. (2022) · Joint Diseases and Related Surgery · doi:10.52312/jdrs.2022.564 · Cited by 7
Yüce, G. E., & Yıldırım, H. (2025) · Journal of Behavioral Medicine · doi:10.1007/s10865-025-00567-w · Cited by 13
“The main goal of diabetes treatment is to prevent & Henry, 2016 ).”
Oliveira, M. K. D. M., Kaizer, U. A. D. O., Jannuzzi, F. F., Gallani, M. C. B. J., Alexandre, N. M. C., Cornélio, M. E., São‐João, T. M., & Rodrigues, R. C. M. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.08.007 · Cited by 9
A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
Johnson, M. L., Bergenstal, R. M., Levy, B. L., & Dreon, D. M. (2022) · Clinical Diabetes · doi:10.2337/cd21-0137 · Cited by 8
Inagaki, N., Nishimoto, T., Nishiya, Y., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2107200 · Cited by 7
“It has been estimated that 45% of patients with T2D fail to meet adequate glycemic control, despite the availability of effective treatments [4].”
BackgroundNielsen, M. H., Jensen, A. L., Pedersen, M. L., & Seibæk, L. (2023) · International Journal of Circumpolar Health · doi:10.1080/22423982.2023.2296706 · Cited by 7
“Previous research has highlighted the issue of medication adherence among people with COPD or T2D [44–46].”
BackgroundHoldt‐Caspersen, N. S., Dethlefsen, C., Vestergaard, P., Hejlesen, O. K., Hangaard, S., & Jensen, M. H. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1185 · Cited by 7
Dehghani, M., Sadeghi, M., Barzkar, F., Maghsoomi, Z., Janani, L., Motevalian, S. A., Loke, Y. K., Ismail‐Beigi, F., Baradaran, H. R., & Khamseh, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1286827 · Cited by 9
“Similarly, adherence is better for insulin pens than for insulin administered by vial and syringe (91, 93).”
BackgroundPauly, T., Lüscher, J., Wilhelm, L. O., Amrein, M. A., Boateng, G., Kowatsch, T., Fleisch, E., Bodenmann, G., & Scholz, U. (2024) · JMIR mhealth and uhealth · doi:10.2196/49576 · Cited by 7
“Poor treatment adherence, in turn, results in higher morbidity and mortality rates, as well as increased expenses related to outpatient care and hospitalization for managing diabetes-related complications [3].”
BackgroundJenkins, M., Simpson, J., Ursuy, T., Hanks, J., & Burroughs, T. (2024) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106241268479 · Cited by 6
A Hybrid Care Model to Manage Diabetes Mellitus in the United Arab Emirates
Almarzooqi, I., Zakaria, H., & Hashemi, A. (2024) · NEJM Catalyst · doi:10.1056/cat.24.0020 · Cited by 7
Gautam, S. K., Paul, R. K., Jain, S., Kumar, V., & Raza, K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04187-8 · Cited by 10
“Commonly prescribed antidiabetic medications include metformin, acarbose, sitagliptin, vildagliptin, and glimepiride, which either regulate blood glucose levels or enhance insulin sensitivity (Alam et al. 2016, 2022; Polonsky and Henry 2016; Akhtar et al. 2018).”
Uddin, S., Machado, M. S., Alshahrouri, B., Echeverri, J. I., Rico, M. C., Rao, A. D., Ruchalski, C., & Barrero, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113822 · Cited by 15
Development and Evaluation of Raft-Forming Rosiglitazone Maleate Tablets for Enhanced Drug Delivery
Parashar, A. K., Tyagi, L. K., & Sethi, V. A. (2025) · Journal of Advanced Scientific Research · doi:10.55218/jasr.2025160305 · Cited by 6
Frías, J. P., Lorenz, M., Roberts, M., DEX, T. A., Schmider, W., Hurst, W., & SKOLNIK, N. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541316 · Cited by 6
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Nelson, D. R., Heaton, P. C., Hincapie, A. L., Ghodke, S. D., & Chen, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01098-8 · Cited by 6
Koehler, J., Hildebrandt, O., Cassel, W., Conradt, R., Mayr, P., Alter, P. J., & Viniol, C. (2021) · Pneumologie · doi:10.1055/a-1666-5369 · Cited by 7
“Diese Therapietreue ist zwar vergleichbar mit anderen Volkskrankheiten wie Hypertonie mit höchstens 60% oder Diabetes mellitus Typ 2 um die 55% [9, 10], doch sollte man bestrebt sein, Gründe oder Auslöser vonTherapiemüdigkeit aufzuzeigen.”
BackgroundKhan, I. I., Pulock, O. S., Pinky, S. D., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271107 · Cited by 6
“As a result, diabetes patients require far more attention and follow-up on a physician’s diagnosis and advice to guarantee proper compliance [2, 4, 5].”
BackgroundRetractedEze, U. I. H., Akhumi, T. F., IHEANACHO, C. O., & Saka, S. A. (2022) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2022.100200 · Cited by 12
Saleem, S. Z., Fareed, A., Akhtar, S. M. M., Farhat, S., Taha, A. M., & Akilimali, A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01305-z · Cited by 8
“Despite the availability of various treatment options, achieving adequate glycemic control remains challenging for many patients due to multiple factors, including poor adherence, fear of injections, hypoglycemia, weight gain, and treatment costs [3–7].”
BackgroundDiabetes care: Inspiration from Sikhism
Kalra, S., Priya, G., Dardi, I., Saini, S. S., Aggarwal, S., Singh, R., Kaur, H., Singh, G., Talwar, V., Singh, P., et al. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_52_17 · Cited by 7
Yousefpour, P., Varanko, A. K., Subrahmanyan, R., & Chilkoti, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000073 · Cited by 6
Risk factors for diabetic retinopathy: a case-control study
Nathani, P. S., Kharat, P. R., & Wadde, S. K. (2024) · Journal of the Egyptian Ophthalmological Society · doi:10.4103/ejos.ejos_38_23 · Cited by 6
Alenazi, F., Peddle, M., Bressington, D. T., Mahzari, M. M., & Gray, R. J. (2021) · Nursing Open · doi:10.1002/nop2.735 · Cited by 5
“Polonsky (2016) also concluded that no specific intervention has consistently been shown to be effective at improving adherence and recommended that a new approach to enhancing adherence be developed to target both treatment-related burden and beliefs about treatment (Polonsky & Henry, 2016).”
BackgroundAssessing Barriers to Medication Adherence Among Latinos with Diabetes: a Cross-sectional Study
Mota, A. B., Sala, E. E. F., Perdomo, J. M., Solis, J. A., Solorzano, W. M., Hochman, M. E., & Reilly, J. M. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05041-3 · Cited by 6
“found that both treatment complexity and convenience are key contributors to decreased adherence.(3) Our findings suggest several potential approaches for improving medication adherence among Latinos with poorly controlled diabetes.”
BackgroundResultHan, K. A., Hwang, Y., Moon, S., Cho, H., Yoo, H. J., Choi, S. H., Chon, S., Kim, K., Kim, T. N., Kang, J. G., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15717 · Cited by 5
The role of medication regimen complexity in diabetes management: a rapid review
Khayyat, S. M., & Ali, R. S. A. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251372294 · Cited by 6
“30 While complex regimens aim to improve glycemic control, a growing body of evidence suggests that the complexity itself can pose significant barriers to medication adherence.”
TİP 2 DİYABETES MELLİTUSLU BİREYLERDE SAĞLIK ALGISI VE AİLE DESTEĞİNİN TEDAVİYE UYUM DÜZEYİNE ETKİSİ
ÇORAK, B., & Uysal, N. (2022) · Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi · doi:10.20492/aeahtd.1098831 · Cited by 6
Uzoigwe, C., Noone, J. M., Liang, Y. M., Ali, S. N., & Gamble, C. L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01322-z · Cited by 5
Conceptualizing Treatment Burden among People with Type 2 Diabetes
Bitterfeld, L., & Reed, S. M. (2024) · Nursing Forum · doi:10.1155/2024/9974083 · Cited by 5
Tang, C., Su, R., Wan, L., Zhu, M., Pu, J., Hao, C., Zhao, J., He, A., Xie, T., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16250 · Cited by 6
“…insulin therapy, is another challenge to insulin therapy in a significant proportion of patients with T2DM owing to the treatment burden of daily subcutaneous injections, 15,16 resulting in delayed initiation of insulin therapy when oral antidiabetic drugs fail to achieve glycaemic targets.”
Cardoso, P., Young, K., Hopkins, R., Mateen, B. A., Pearson, E. R., Hattersley, A. T., McKinley, T. J., Shields, B. M., & Dennis, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16470 · Cited by 5
“9,12 Although multiple other factors can lead to a perceived lack of medication efficacy or access to medication, 4,13 short-term side-effects are likely the main reason for early discontinuation.”
Sweeney, M. D., Cole, G. D., Pabari, P., Hadjiphilippou, S., Tayal, U., Mayet, J., Chapman, N., & Plymen, C. M. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13284 · Cited by 5
Thomas, T., Dyer, W. T., Yassin, M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2686 · Cited by 5
Renaldi, F. S., Riyadina, W., Qamar, M., & Sauriasari, R. (2021) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v8i1.1105 · Cited by 7
“Treatment activity is how the interaction between patients and health workers is linked (Polonsky & Henry, 2016).”
BackgroundNoori, A. J., Kadhim, D. J., & Al-Hilal, M. A. (2022) · F1000Research · doi:10.12688/f1000research.124941.1 · Cited by 5
“Previous studies showed that high MRB leads to decreased medication adherence,(19,22) and the nonadherence tomedication increases emergency room visits and hospitalization.(30) Patients with uncontrolled blood glucose (high HbA1c), neuropathy, or retinopathy had significantly higher medication burdens.”
Roshi, D., Burazeri, G., Italia, S., Schröder‐Bäck, P., Ylli, A., & Brand, H. (2021) · Eastern Mediterranean Health Journal · doi:10.26719/emhj.21.008 · Cited by 5
Chen, J., Borra, S., Huang, A., Fan, L., Pollom, R. D., & Hood, R. C. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01209-z · Cited by 6
“These compliance barriers have been directly associated with poor glycemic control, which are further associated with adverse clinical and economic outcomes [2, 6].”
BackgroundRole of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome
Panda, S. P. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220531123116 · Cited by 6
Hung, W.-T., Chen, Y.-J., Cheng, C.-Y., Ovbiagele, B. I., Lee, M., & Hsu, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109937 · Cited by 9
Evaluation of Medication Adherence and its Related Factors among Type 2 Diabetic Patients
Movaghar, S. K., Khazaei, S., & Borzouei, S. (2021) · مجله پزشکی بالینی ابن سینا · doi:10.52547/ajcm.28.3.158 · Cited by 5
Mendonça, I. R., Rosendo, A. B., da Silva, B. B., & Iser, B. P. M. (2023) · DEMETRA Alimentação Nutrição & Saúde · doi:10.12957/demetra.2023.70199 · Cited by 12
Min, J. Y., Griffin, M. R., Chipman, J., Hackstadt, A. J., Greevy, R. A., Grijalva, C. G., Hung, A. M., & Roumie, C. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13853 · Cited by 5
Patient Adherence: Challenges, Myths, and Realities
Rodríguez‐Saldaña, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_24 · Cited by 5
A Systems Thinking Perspective of Medication Adherence for Patients with Diabetes Mellitus
Ferreira, S., & Castleberry, G. (2019) · Procedia Computer Science · doi:10.1016/j.procs.2019.05.073 · Cited by 5
At-Home Breath Data Collection for Signatures of Type 2 Diabetes: A Pilot Clinical Study
Naser, S., Roberts, D. A., & Shrestha, S. (2025) · Biosensors · doi:10.3390/bios15030149 · Cited by 5
“Poor medication adherence has been linked to increased costs related to emergency room (ER) visits, outpatient care, hospitalization, and the management of T2DM complications, ultimately contributing to increased mortality [5].”
Donnelly, L. A., Singh, K., McCrimmon, R. J., & Pearson, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70269 · Cited by 7
“24 Social deprivation is a well-established barrier to adherence, and it is notable that in Scotland, where prescriptions are free, financial cost is unlikely to be the primary driver — suggesting that other structural or behavioral factors may be contributing.”
Archer, M., & Llahana, S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.01.002 · Cited by 6
Alper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
“Oral semaglutide, co-formulated with Sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC), achieved marked bioavailability but requires fasting and 30-minute post-dose restrictions, reducing flexibility [13, 15].”
Chan, J. C. N., Deerochanawong, C., Khunti, K., Hassanein, M. M., & Mohan, V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113173 · Cited by 9
Schenaarts, L., Hendriks, F. K., Fuchs, C. J., Sluijsmans, W. E., Snijders, T., & van Loon, L. J. C. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2406-4491 · Cited by 4
“Nearly 45 % of individuals with T2DM fail to achieve recommended blood glucose levels (HbA1c 53 mmol HbA1c/mol Hb) [2].”
Regufe, V. M. G., Lobão, M. A. R., Martins, N. A., Luís, C., HAFE, P. V., & Pinto, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216423 · Cited by 12
“In addition, the stress and comorbidities associated with diabetes may further complicate disease management [13].”
BackgroundDrug-related problems among type 2 diabetic patients in Sunwal Municipality of Western Nepal
Chapagain, S., Pathak, N., Subedi, K., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309781 · Cited by 4
Raja, S., Raja, A., Ali, A., & Asghar, M. S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01602-y · Cited by 5
“Patient reluctance toward insulin therapy, driven by concerns about injections, treatment complexity, potential weight gain, and fears of hypoglycemia, often hinders the achievement of optimal glycemic control in diabetes by impacting adherence and persistence [24–26].”
Lim, S. K., Nam, G. E., & Sharma, A. M. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0278 · Cited by 6
“Despite widespread availability and funding for diabetes treatments, reduced adherence and poor glycemic control may stem from limited disease awareness, prior negative experiences, or concerns about medication side effects [24,25].”
Ansari, M. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i331154 · Cited by 6
“microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (cardiovascular) complications on long-term [1,7].”
BackgroundTran, T. T. N., Ngo, T. K. C., Nguyen, T. T., Diep, T. H., Vo, T. H. P., Lê, V. A., Dương, T. N. L., Nguyen, T. Y. N., & Lê, C. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.24 · Cited by 6
Shapira, A., Kane, N. S., Tanenbaum, M. L., Hoogendoorn, C. J., & Gonzalez, J. S. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108205 · Cited by 5
Bongaerts, B. W. C., Kuß, O., Bonnet, F., Chen, H., Cooper, A., Fenici, P., Gomes, M. B., Hammar, N., Ji, L., Khunti, K., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15050 · Cited by 5
“Regarding the effect of age on outcomes among people with T2D, previous studies have shown a more severe metabolic phenotype in younger individuals than in their older counterparts,(20) as well as lower levels of treatment adherence.(21) Furthermore, data from Project Dulce in the United States revealed that people wi…”
ResultChallenges to Lifestyle Medicine for Type 2 Diabetes in Iran: A Synoptic Review
Firouzabadi, M. D., Sheikhy, A., Poopak, A., Esteghamati, A., Mechanick, J. I., & Firouzabadi, F. D. (2023) · American Journal of Lifestyle Medicine · doi:10.1177/15598276231167787 · Cited by 5
“33 Fortunately, modern injection devices for insulin and other non-insulin diabetes medications are easy to use and can mitigate adherence issues.”
Kindratt, T. B., Boateng, G. O., Brannon, G. E., Sankuratri, B. Y. V., & Brown, K. K. (2023) · PEC Innovation · doi:10.1016/j.pecinn.2023.100185 · Cited by 8
“However, when PPC is poorly managed, it could lead to diabetes distress [20] or non-adherence to medication [21,22].”
BackgroundAlfakhri, A., Almadani, O. A., Althunian, T. A., Alrwisan, A. A., Badreldin, H. A., & Albogami, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111770 · Cited by 5
Teo, V., Weinman, J. A., & Yap, K. Z. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.111969 · Cited by 5
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
“These variables include the number of injections administered, the administration device, the size of the needle, its effectiveness, any gastrointestinal side effects, safety, and cost-effectiveness [84,85] .”
Abunada, S., Bai, S., Kumari, U., Nancy, F., Khan, A., Bai, N., Shevani, F. N. U., Bai, A., Dev, S., Abiddin, N. Z. U., et al. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70067 · Cited by 4
Pamungkas, R. A., & Chamroonsawasdi, K. (2020) · Frontiers of Nursing · doi:10.2478/fon-2020-0015 · Cited by 13
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.